In Friday’s Wall Street session, Gilead Sciences, Inc (NASDAQ:GILD) shares traded at $110.08, down -0.93% from the previous session.
GILD stock price is now 4.21% away from the 50-day moving average and 15.45% away from the 200-day moving average. The market capitalization of the company currently stands at $136.93B.
On March 04, 2025, Oppenheimer reiterated its ‘Outperform’ rating on the stock by increasing its target price from $115 to quote $132, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, DANIEL O’DAY, Officer bought 10,000 shares of the company’s stock on May 30 ’25. The stock was bought for $1,104,192 at an average price of $110.42. An SEC document containing details of the transaction can be found on the SEC’s website. On May 22 ’25, Chief Commercial Officer Mercier Johanna sold 28,000 shares of the business’s stock. A total of $3,010,564 was realized by selling the stock at an average price of $107.52. This leaves the insider owning 121,152 shares of the company worth $13.34 million. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $119.96. As of last week, the company has a debt-to-equity ratio of 1.30, a current ratio of 1.37, and a quick ratio of 1.23.
The net profit margin was 20.79% and return on equity was 32.51% for GILD. The company reported revenue of $6.67 billion for the quarter, compared to $6.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.28 percent.
